DERMTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6031 USD | +3.02% |
|
-6.35% | -65.54% |
| 04-22 | North American Morning Briefing : Stock Futures -2- | DJ |
| 04-19 | Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63 | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -65.54% | 20.88M | C | ||
| +1.39% | 12.8B | B+ | ||
| -10.29% | 7.61B | B- | ||
| +3.71% | 5.41B | B | ||
| -1.16% | 4.51B | C | ||
| +5.74% | 4.49B | C | ||
| +12.21% | 2.73B | - | - | |
| -14.48% | 2.02B | B- | ||
| -11.50% | 1.73B | D+ | ||
| -5.02% | 1.64B | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DMTK Stock
- Ratings DermTech, Inc.
